Imunon Inc. recently faced a potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement and minimum stockholders' equity requirement. The company received a delisting determination letter on May 28, 2025, indicating that unless a hearing was requested, trading of its common stock would be suspended on June 6, 2025. Imunon Inc. requested a hearing on May 29, 2025, to appeal the delisting determination and seek a suspension of delisting pending its return to compliance. The hearing request has stayed the suspension of trading, allowing the company's stock to remain listed on Nasdaq until the Panel delivers a decision. In a positive development, warrant exercises provided Imunon Inc. with $2.0 million in proceeds, raising its stockholders' equity to $3.0 million as of May 31, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.